Life Sciences & Healthcare


We represent both domestic and foreign companies as well as multinationals from a wide range of industry sectors. We also act on behalf of a number of governments and international organisations. We also aim at providing the best legal services in complicated transactions and demanding dispute resolution in our jurisdiction.
page background: 
White heading text: 
Eight Edition of The Best Lawyers in Finland

The Best Lawyers® has recognized D&I's Partner Johan Åkermarck in the Eight Edition of The Best Lawyers in Finland in the field of Biotechnology Law. Recognition by Best Lawyers is based entirely on peer review.

Best Lawyers® 8th Edition of The Best Lawyers in Finland

D&I and 13 of its lawyers recognized by Best Lawyers® in the 8th edition of The Best Lawyers in Finland for the following listed categories: Environmental Law, Biotechnology Law, Mergers and Acquisitions Law, Private Equity Law, Corporate Law, Information Technology Law, Media Law, Technology Law, Telecommunications Law, Tax Law, Banking and Finance Law, Arbitration and Mediation, Competition Law, Labor and Employment Law and Litigation.

D&I Competition and Life Sciences & Healthcare Alert 15 June 2017

D&I Alert (in Finnish): Sote-toimialalle väliaikainen velvollisuus ilmoittaa yrityskaupat KKV:lle

D&I Alert (in English): Temporary Obligation to Notify Concentrations to the FCCA on Social and Health Care Sector

D&I Life Sciences Alert 12 May 2017

D&I Alert: The Finnish Government Publishes Proposal on Patient's Freedom of Choice

Who’s Who Legal 2017 - Life Sciences

D&I's Partner Johan Åkermarck, Head of Life Sciences & Healthcare, has been recognized as a leading expert in the Who’s Who Legal 2017 editions of: Life Sciences - Transactional and Life Sciences - Regulatory .  Who's Who Legal identifies the foremost legal practitioners in business law based upon comprehensive, independent research.

D&I Life Sciences Alert on 23 Dec 2016

D&I Alert: The Finnish Government Publishes Draft Proposal on Patient's Freedom of Choice

Who's Who Legal: Life Sciences 2016

D&I is the only Finnish law firm listed in the Transactional -category of Who's Who Legal: Life Sciences 2016. Partners Johan Åkermarck and Mikko Eerola are listed as leading experts in Finland.

D&I Life Sciences Alert 21 Dec 2015

D&I Life Sciences Alert by D&I's Partner Johan Åkermarck and the Life Sciences & Healthcare practice on the latest Finnish updates 2015 of this practice area.

Adelis Equity Partners

D&I advises Adelis Equity Partners Fund I in its acquisition of a majority stake in Med Group Oy, one of the fastest growing healthcare services companies in Finland, from Terveysrahasto Oy and the company’s two founders. The founders together with the broader management team continue to own a significant part of the company. The company caters to the public sector as well as individual customers across Finland.

Karolinska Development

D&I advised Karolinska Development AB, the Swedish listed Life Sciences company when it closed its financing round in the Finnish drug development company Forendo Pharma Oy, which announced the successful closing of the EUR 12 million financing round. Novartis Venture Fund and MS Ventures participates in the financing round, alongside the current major shareholders Karolinska Development AB, Novo Seeds and Finnvera.

Advising Karolinska Development

We advised Karolinska Development, a Swedish listed medical company, in its investment into Forendo Pharma, a new drug development company based in Finland.


D&I advised Mendor, a leading company in new diabetes technologies and services, in relation to its EUR 8.1 million venture capital financing.

Leading Pharmaceutical Companies

D&I continuously advises some of the world's leading pharmaceutical companies in all fields of Finnish pharmaceutical and business law.

Legal Aspects Relating to Entering the Finnish Market

We advised an orphan drug company with the legal aspects relating to entering the Finnish market.

Medical Device Companies

D&I advises several of the world's leading medical device companies in all fields of their Finnish life sciences businesses.

Leading International Pharmaceutical Companies - Reorganisation

We have represented leading international pharmaceutical companies in the establishment, acquisition and reorganization of operations in Finland, including regulatory, corporate and contractual work.

Cross-border Merger of Pharmaceutical Distributors

We acted for a Nordic state-controlled distributor of pharmaceuticals in its cross-border merger with a leading Finnish distributor, creating the largest pharmaceuticals distributor in the Nordic countries.

Advising a Pioneering Biotechnology Venture

We advised a pioneering biotechnology venture in Finland in all legal aspects of its operations, including capitalization, public funding, and patents and other intellectual property.

The Sale Finland's Largest Social Care Services Company

D&I advises Finnish private equity firm MB Funds and other owners in the sale of Finland's largest social care services company Mainio Vire (formerly Medivire Hoiva) to British private equity investor HgCapital.

Advising Companies Before the Authorities

We advised a pharmaceutical company with subsidy issues before the Pharmaceutical Pricing Board.

Advisor for Private Hospitals

D&I advises private hospitals on compliance issues and medical practice issues.

Advisor in Sale of a Healthcare Company

D&I advised the seller of Medivire Työterveyspalvelut, a major healthcare company, in a EUR 127 million sale to Suomen Terveystalo.

Ratos - Perlos

D&I advised Ratos, the Swedish listed private equity house, in the EUR 67 million acquisition of the Health Care Division of Perlos, the leading Finnish contract manufacturer and the related EUR 60 million add-on acquisition of Medisize, a Swiss healthcare company.

Pharmaceutical Companies and Competition Law

D&I continuously advises companies in the pharmaceutical field, for instance, relating to dominance issues, distribution arrangements and public procurement matters.


D&I advises AstraZeneca in the Finnish aspects of its approximately USD 1.8 billion cash sale of Astra Tech to DENTSPLY International.